DRUG INDUSTRY

Amendments

Vaccine injury: compensation (S. 1922), 31642 [21NO]

Analyses

Vaccine Injury Compensation Amendments (S. 1922), 29877-29879 [17NO]

Articles and editorials

Act of Mercy, 674 [25JA]

Heroin for the Terminally Ill, 675 [25JA]

Hope's Only Messenger, 22055 [27SE]

In Defense of Reintroduction of Heroin Into American Medical Practice and H.R. 5290—Compassionate Pain Relief Act, 675 [25JA]

Pharmaceutical Industry's ``Me Too'' Drugs, 16837 [31JY]

Relief for Terminally Ill, 674 [25JA]

Why Not Heroin? Controversy Surrounding Legalization of Heroin for Therapeutic Purposes, 677-683 [25JA]

Bills and resolutions

Compassionate Pain Relief Act: enact (see S. 67)

Dept. of HHS: fees for review of applications for marketing approval of certain medical products (see H.R. 2482)

Diethylstilbestrol: Federal grants for programs to benefit certain individuals (see H.R. 730)

Federal Food, Drug, and Cosmetic Act: amend (see H.R. 273)

Medical Technology Competitiveness Act: enact (see S. 622)

Product safety: require food and drug manufacturers to maintain toll-free telephone line for inquiries (see H.R. 240)

Vaccine injury: compensation (see S. 1922)

Court decisions

Roche Products v. Bolar Pharmaceutical Co., 4592 [16MR]

Letters

Prescription drug prices: Gerald J. Mossinghoff, Pharmaceutical Manufacturers Association, 16839 [31JY]

Memorials of legislature

California, 27669 [7NO]

Papers

Prescription Drug Prices—Are We Getting Our Money's Worth? Committee on Aging (Senate, Special), 16839 [31JY]

Remarks in House

Acquired immune deficiency syndrome: accessibility of treatment, 22055 [27SE]

Burroughs Wellcome Co.: investigation of AZT price monopoly, 20722 [19SE]

Cuba: exception to embargo on trade relative to medicines or medical supplies (H.R. 1853), 6337 [12AP]

Dept. of HHS: fees for review of applications for marketing approval of certain medical products (H.R. 2482), 10175 [24MY]

New Jersey: health products manufacturing industry, 20231 [12SE]

Remarks in Senate

Acquired immune deficiency syndrome: AZT drug treatment, 5389 [4AP]

Compassionate Pain Relief Act: enact (S. 67), 672 [25JA]

Drug abuse: relationship between legal and illegal drug use, 22980, 22981 [3OC]

FDA Revitalization Act: enact (S. 845), 7277 [19AP]

FDA: drug approval process, 7921 [3MY]

Medical Technology Competitiveness Act: enact (S. 622), 4592 [16MR], 5615 [5AP]

Prescription drugs: pricing, 16837-16841 [31JY]

Vaccine injury: compensation (S. 1922), 29877 [17NO]

Reports

Patent for Medical Devices: ABA, 4592 [16MR]

Tax Havens and Manufacturing Strategy for New Drugs: Warner Lambert Drug Co., 16840 [31JY]

Statements

New Drugs Priced Higher Than Older Medications: Hambrecht & Quist, 16838 [31JY]

Profitability for Pharmaceutical Industry: Hambrecht & Quist, 16837 [31JY]

———Rothchild, Unterberg, and Towbin, 16837 [31JY]

Rollin/Shapiro To Aid NCTIP, National Committee on the Treatment of Intractable Pain, 677 [25JA]

Tables

Range of market prices paid for brand name prescription drugs, spring 1989, 16838 [31JY]

Texts of

S. 67, Compassionate Pain Relief Act, 672, 673 [25JA]

S. 622, Medical Technology Competitiveness Act, 4593 [16MR]

S. 845, FDA Revitalization Act, 7278-7280 [19AP]